Imagine having a digital copy of a patient's body that doctors can use to test cancer treatments before actually giving them to the person. This tool acts like a flight simulator for 'living drugs,' predicting how a patient's immune system will react to modified cells. It helps doctors move away from guessing and toward a precise plan tailored to each individual.
CAR T-cell therapies are effective but unpredictable, with some patients failing to respond or suffering severe toxicities. Doctors currently rely on a trial-and-error approach because they lack tools to predict individual patient reactions.
A multi-scale virtual twin prototype for multiple myeloma patients. It is a modular software system that uses molecular data to simulate how 'living drugs' interact with a specific patient.
If you are a biotech company dealing with unpredictable patient responses to CAR T cells — this project developed a virtual twin prototype that predicts treatment outcomes. This allows for better risk-adapted decision support during the drug development process.
If you are a software provider dealing with the need for precision medicine tools — this project developed a modular software architecture for virtual twins. It follows software as medical device principles to ensure the prototype can be scaled for clinical use.
If you are a hospital dealing with severe toxicities in multiple myeloma patients — this project developed a multi-scale model that integrates real-world molecular data. This helps health experts identify the most effective course of therapy for each patient.
Based on available project data, pricing and cost details are not provided as the project is currently in the research and prototype development phase.
The project uses a modular software architecture and extensible ontologies, which the objective states makes the model easily transferable to other indications and cellular immunotherapies.
Based on available project data, specific licensing terms are not listed, but the project is developing a research-use-only prototype following software as medical device principles.
The virtual twin is designed to be integrated into the Digital Europe Programme ecosystem and supports decision-making from diagnosis through to late patient monitoring.
The project period runs from 2023-12-01 to 2028-05-31, aiming to reach technology readiness level 6 by the end of the term.
The consortium is well-balanced for a translation project, consisting of 17 partners across 8 countries. With a 29% industry ratio (5 companies, including 4 SMEs), there is a strong link between the 6 universities and 4 research institutes and the commercial market, ensuring the software is developed with practical application in mind.
Contact Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung EV
Contact us to explore licensing opportunities for the CAR T virtual twin prototype.
